Rovatirelin - Kissei Pharmaceutical
Alternative Names: KPS-0373; S-0373; Thyrotropin-releasing hormone derivative; TSH derivativeLatest Information Update: 05 Nov 2023
At a glance
- Originator Shionogi
- Developer Kissei Pharmaceutical; Shionogi
- Class Oxazolidinones; Pyrrolidines; Small molecules; Thiazoles
- Mechanism of Action Thyrotropin-releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Submission Withdrawal Spinocerebellar degeneration
- Discontinued Parkinson's disease
Most Recent Events
- 21 Jul 2023 Regulatory submission withdrawn for Spinocerebellar degeneration in Japan (PO)
- 26 Apr 2022 Rovatirelin is still in preregistration for Spinocerebellar degeneration in Japan (PO) (Kissei Pharmaceuticals pipeline, April 2022)
- 23 Dec 2021 Kissei Pharmaceutical submits New Drug Application (NDA) for Rovatirelin for Spinocerebellar degeneration